Market Overview:
The global C difficile infection drug market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of C difficile infections, rising demand for novel drugs, and growing awareness about available treatment options. The global C difficile infection drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into metronidazole, vancomycin, fidaxomycin, and others. Metronidazole held a dominant position in 2017 owing to its high efficacy and low cost as compared to other drugs in this category. However, fidaxomycin is expected to witness high growth during the forecast period due its superior efficacy against various strains of C difficile bacteria as well as its safety profile. On the basis of application, pre-treatment accounted for a major share in 2017 owing to early diagnosis and initiation of treatment before symptoms worsen significantly.
Product Definition:
C difficile infection is a type of bacterial infection that can cause severe diarrhea. The infection is caused by the bacterium Clostridium difficile, which is found in the gut flora of healthy people. However, when antibiotics are taken they can kill off other bacteria in the gut, allowing C difficile to overgrow and cause infection. C difficile infections can be serious and even life-threatening, especially in elderly patients or those with weakened immune systems. Treatment typically involves antibiotics to kill the bacteria as well as aggressive supportive care to treat dehydration and other symptoms.
Metronidazole:
Metronidazole, it's usage and growth factor in C difficile infection drug market is expected to grow at a significant rate over the forecast period. The increasing prevalence of chronic diseases such as cancer, diabetes and autoimmune disorders coupled with the growing geriatric population base is anticipated to drive the global metronidazole market. In addition, favorable government initiatives are also expected to boost demand for metronidazole over the forecast period.
Vancomycin:
Vancomycin is an antibiotic drug and is used in the treatment of bacterial infections. It works by killing the bacteria that causes infection. The drug has a wide range of applications, including skin infections, pneumonia, and food poisoning among others. In recent years vancomycin has gained popularity as a treatment for C difficile infection (CDI). According to research data published in NCBI; CDI affects around 1-2% of patients taking antibiotics for any illness.
Application Insights:
The pre-treatment segment dominated the global market in 2017. This can be attributed to an increase in hospital admissions for C difficile infections and rising demand for antibiotics. According to a study published by NCBI, it is estimated that around 15% of patients develop Clostridium difficile infection (CDI) after receiving antibiotic treatment, which requires some form of preventive therapy before the onset of symptoms.
Preventive measures taken prior to diagnosis help reduce the risk of developing CDI post completion antibiotic course. The use of metronidazole is one such measure adopted by healthcare professionals worldwide owing to its effectiveness in preventing recurrence as well as mortality associated with this condition.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players, high awareness levels regarding CDI treatment, and availability of reimbursement facilities are some factors attributing to its largest share. In addition, increasing incidence rates due to various factors such as changes in lifestyle and unhealthy diet are also contributing towards the growth of this disease is North America.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with growing health awareness among people especially patients suffering from CDI infection. Moreover, government initiatives for improving healthcare infrastructure along with increasing R&D activities by pharmaceutical companies for developing novel drugs will drive this regional market during the forecast period.
Growth Factors:
- Increasing incidence of C difficile infection
- Rising demand for novel and effective drugs for the treatment of C difficile infection
- Growing number of clinical trials for new drug therapies for C difficile infection
- increasing healthcare expenditure
- rising awareness about the prevention and treatment of C difficile infection
Scope Of The Report
Report Attributes
Report Details
Report Title
C Difficile Infection Drug Market Research Report
By Type
Metronidazole, Vancomycin, Fidaxomycin, Others
By Application
Pre-treatment, Mid-term treatment, Others
By Companies
Merck, Astellas, Eli Lilly, ANI Pharmaceutical, Flynn Pharma, Aspen Pharmacare, Akorn, Merus labs, Pfizer, AstraZeneca, Merck, Sanofi, Fresenius, Xellia, Zhejiang Medicine, Lupin
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
133
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global C Difficile Infection Drug Market Report Segments:
The global C Difficile Infection Drug market is segmented on the basis of:
Types
Metronidazole, Vancomycin, Fidaxomycin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pre-treatment, Mid-term treatment, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Astellas
- Eli Lilly
- ANI Pharmaceutical
- Flynn Pharma
- Aspen Pharmacare
- Akorn
- Merus labs
- Pfizer
- AstraZeneca
- Merck
- Sanofi
- Fresenius
- Xellia
- Zhejiang Medicine
- Lupin
Highlights of The C Difficile Infection Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Metronidazole
- Vancomycin
- Fidaxomycin
- Others
- By Application:
- Pre-treatment
- Mid-term treatment
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the C Difficile Infection Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
C difficile infection drug is an antibiotic that is used to treat infections caused by C difficile bacteria. This medication can be taken by mouth or injected into a vein. It works by killing the bacteria responsible for causing the infection.
Some of the key players operating in the c difficile infection drug market are Merck, Astellas, Eli Lilly, ANI Pharmaceutical, Flynn Pharma, Aspen Pharmacare, Akorn, Merus labs, Pfizer, AstraZeneca, Merck, Sanofi, Fresenius, Xellia, Zhejiang Medicine, Lupin.
The c difficile infection drug market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 C Difficile Infection Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 C Difficile Infection Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 C Difficile Infection Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the C Difficile Infection Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global C Difficile Infection Drug Market Size & Forecast, 2018-2028
4.5.1 C Difficile Infection Drug Market Size and Y-o-Y Growth
4.5.2 C Difficile Infection Drug Market Absolute $ Opportunity
Chapter 5 Global C Difficile Infection Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 C Difficile Infection Drug Market Size Forecast by Type
5.2.1 Metronidazole
5.2.2 Vancomycin
5.2.3 Fidaxomycin
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global C Difficile Infection Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 C Difficile Infection Drug Market Size Forecast by Applications
6.2.1 Pre-treatment
6.2.2 Mid-term treatment
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global C Difficile Infection Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 C Difficile Infection Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America C Difficile Infection Drug Analysis and Forecast
9.1 Introduction
9.2 North America C Difficile Infection Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America C Difficile Infection Drug Market Size Forecast by Type
9.6.1 Metronidazole
9.6.2 Vancomycin
9.6.3 Fidaxomycin
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America C Difficile Infection Drug Market Size Forecast by Applications
9.10.1 Pre-treatment
9.10.2 Mid-term treatment
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe C Difficile Infection Drug Analysis and Forecast
10.1 Introduction
10.2 Europe C Difficile Infection Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe C Difficile Infection Drug Market Size Forecast by Type
10.6.1 Metronidazole
10.6.2 Vancomycin
10.6.3 Fidaxomycin
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe C Difficile Infection Drug Market Size Forecast by Applications
10.10.1 Pre-treatment
10.10.2 Mid-term treatment
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific C Difficile Infection Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific C Difficile Infection Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific C Difficile Infection Drug Market Size Forecast by Type
11.6.1 Metronidazole
11.6.2 Vancomycin
11.6.3 Fidaxomycin
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific C Difficile Infection Drug Market Size Forecast by Applications
11.10.1 Pre-treatment
11.10.2 Mid-term treatment
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America C Difficile Infection Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America C Difficile Infection Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America C Difficile Infection Drug Market Size Forecast by Type
12.6.1 Metronidazole
12.6.2 Vancomycin
12.6.3 Fidaxomycin
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America C Difficile Infection Drug Market Size Forecast by Applications
12.10.1 Pre-treatment
12.10.2 Mid-term treatment
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) C Difficile Infection Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) C Difficile Infection Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) C Difficile Infection Drug Market Size Forecast by Type
13.6.1 Metronidazole
13.6.2 Vancomycin
13.6.3 Fidaxomycin
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) C Difficile Infection Drug Market Size Forecast by Applications
13.10.1 Pre-treatment
13.10.2 Mid-term treatment
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 C Difficile Infection Drug Market: Competitive Dashboard
14.2 Global C Difficile Infection Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Astellas
14.3.3 Eli Lilly
14.3.4 ANI Pharmaceutical
14.3.5 Flynn Pharma
14.3.6 Aspen Pharmacare
14.3.7 Akorn
14.3.8 Merus labs
14.3.9 Pfizer
14.3.10 AstraZeneca
14.3.11 Merck
14.3.12 Sanofi
14.3.13 Fresenius
14.3.14 Xellia
14.3.15 Zhejiang Medicine
14.3.16 Lupin
